About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 1

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

A Phase I Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Solid Tumors

NCT02261220•MedImmune LLC

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Advanced Solid Tumors

Interventions

MEDI4736

tremelimumab

Locations

75

United States

Locations (75)

Research Site

Scottsdale, Arizona, United States

Research Site

Duarte, California, United States

Research Site

La Jolla, California, United States

Research Site

Los Angeles, California, United States

Research Site

Los Angeles, California, United States

Research Site

Whittier, California, United States

Key Dates

Start Date

October 13, 2014

Primary Completion Date

January 27, 2020

Completion Date

January 27, 2020

Last Updated

March 6, 2020

Related Studies

RECRUITINGPhase 1/2

A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.

NCT06898450

Advanced Solid Tumors CancerMSI-H Cancer

RECRUITINGPhase 1

A Study of ASP1002 in Adults for Treatment of Solid Tumors

NCT05719558

Advanced Solid Tumors

RECRUITINGPhase 1

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

NCT07029399

HR+ Breast CancerTriple Negative Breast Cancer (TNBC)+5 more

RECRUITINGPhase 1/2

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

NCT04826341

HRD CancerSCLC+1 more

RECRUITINGPhase 1/2

Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

NCT06819735

Advanced Solid Tumors

RECRUITINGPhase 2

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06760819

Advanced Solid TumorsHER2 Mutation

View all related studies

Sponsors

Lead Sponsor

MedImmune LLC

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 6, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions